Vivo Capital has previously backed biotechs acquired by big pharma in billion-dollar deals.
This move comes a day after President Trump signed an executive order to streamline approval processes for domestic plants.
At a time when investment has been low in biotech, establishing and maintaining good relationships with investors is vital.
The designation was granted based on preliminary clinical evidence from an ongoing dose-escalation open-label Phase I/II trial.
The partnership will explore the use of THT with DPX formulation as a carrier for neoantigens.
The spray has a shelf life of two years and can withstand temperature exposures up to 122°F (50°C).
